Claudia A. Hawkins

Dr. Claudia A. Hawkins


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in AIDS
Verified
Journal Article
Closed access
CHClaudia A. Hawkins
Claudia A. Hawkins
GCGuerino Chalamilla
Guerino Chalamilla
JOJames Okuma
James Okuma
DSDonna Spiegelman
Donna Spiegelman
EHEllen Hertzmark
Ellen Hertzmark
WFWafaie Fawzi
Wafaie Fawzi
To determine the relationship between sex and antiretroviral therapy (ART) outcomes in an urban Tanzanian setting. Longitudinal analysis of a cohort of HIV-infected adult men and women on ART enrolled at the Management and Development for Health (MDH)-President's Emergency Plan For AIDS Relief (PEPFAR) HIV care and treatment program in Dar es Salaam, Tanzania. Clinical and immunologic responses to ART were compared between HIV-infected men and women enrolled from November 2004 to June 2008. Cox regression analyses were used to study sex differences with regard to mortality, immunologic failure (WHO, 2006) and loss to follow-up, after adjusting for other risk factors for the outcomes. Four thousand, three hundred and eighty-three (34%) men and 8459 (66%) women were analyzed. Men were significantly more immunocompromised than women at enrollment in terms of stage IV disease (27 vs. 23%, P < 0.001) and mean CD4⁺ cell count (123 vs. 136 cells/μl, P < 0.001). In multivariate analyses, men had a significantly higher risk of overall mortality [hazard ratio 1.19, 95% confidence interval (CI) 1.05-1.30, P < 0.001], immunologic nonresponse defined as CD4 cell count less than 100 cells/μl after at least 6 months of initiating ART (hazard ratio 1.74, 95% CI 1.44-2.11, P < 0.001) and loss to follow-up (hazard ratio 1.19, 95% CI 1.10-1.30, P < 0.001) than that in women. Associations did not change significantly when restricting analyses to the period of good adherence for all patients. Nonadherence to care and advanced immunodeficiency at enrollment explained only 17% of the inferior mortality in HIV-infected men in this resource-limited setting. Additional study of behavioral and biologic factors that may adversely impact treatment outcomes in men is needed to reduce these sex disparities.

24 September 2007 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
CHClaudia A. Hawkins
Claudia A. Hawkins
JHJenny Huang
Jenny Huang
NJNancy Jin
Nancy Jin
GNGary A. Noskin
Gary A. Noskin
TZTeresa R. Zembower
Teresa R. Zembower
MBMaureen Bolon
Maureen Bolon
Research from JAMA Internal Medicine — Persistent Staphylococcus aureus Bacteremia — An Analysis of Risk Factors and Outcomes

27 March 2013 in AIDS
Verified
Journal Article
Closed access
CHClaudia A. Hawkins
Claudia A. Hawkins
BCBeatrice Christian
Beatrice Christian
JYJitao Ye
Jitao Ye
TNTumaini Nagu
Tumaini Nagu
EAEric Aris
Eric Aris
WFWafaie Fawzi
Wafaie Fawzi
Objectives: To evaluate the prevalence of HIV/hepatitis B virus (HBV) co-infection and relationship between HIV/HBV and health outcomes in a cohort of HIV-infected adults receiving antiretroviral treatment (ART) in urban Tanzania. Design/methods: Clinical and immunologic responses to ART were compared longitudinally between HIV mono (HIV) and HIV/HBV co-infected (HIV/HBV) adults enrolled between November 2004 and September 2011 at the Management and Development for Health (MDH)-PEPFAR HIV Care and Treatment program in Dar es Salaam, Tanzania. Results: The prevalence of HIV/HBV co-infection was 6.2% (1079/17 539). Compared to HIV patients, HIV/HBV patients were more likely to be male, younger, and more immunosuppressed at ART initiation. Median ART duration was 18.6 [interquartile range (IQR) 4.9–29.5] and 18.2 (IQR 4.2–27.2) months in HIV and HIV/HBV patients, respectively. In multivariate analyses, a trend towards a higher risk of mortality was observed in HIV/HBV patients {hazard ratio 1.18 [95% confidence interval (CI) 0.98–1.42], P = 0.07} as well as lower CD4+ cell counts throughout recovery (P < 0.01) and higher risk of moderate-to-severe hepatotoxicity (P values < 0.01 for alanine transaminase > 120 and >200 IU/l). There was a higher risk of mortality in HIV/HBV patients vs. HIV patients on non-tenofovir (TDF)-containing ART [hazard ratio 1.28 (95% CI 1.02–1.61), P < 0.03], whereas there was no difference in the risk of mortality observed in HIV/HBV patients vs. HIV patients on TDF-containing ART [hazard ratio 0.70 (95% CI 0.34–1.44), P < 0.33]; interaction P = 0.30. Conclusions: HBV co-infection significantly impacted ART outcomes in this Tanzanian HIV-infected population. Further research is needed to confirm the potential beneficial effects of TDF on mortality in HIV/HBV co-infected individuals in these settings.

1 July 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
CHClaudia A. Hawkins
Claudia A. Hawkins
CAChad Achenbach
Chad Achenbach
WFWilliam Fryda
William Fryda
DNDuncan DrPH Ngare
Duncan DrPH Ngare
RMRobert Murphy
Robert Murphy
Background: Insufficient data exist on the durability and tolerability of first-line antiretroviral therapy (ART) regimens provided by HIV treatment programs implemented in developing countries. Methods: Longitudinal observation of clinical, immunologic, and treatment parameters of all HIV-infected adult patients initiated on ART was performed at Saint Mary's Mission Hospital in Nairobi, Kenya from September 2004 until August 2006. Results: A total of 1286 patients were analyzed (59.1% female). Initial ART regimens were primarily stavudine, lamivudine, and nevirapine (62.1%). Median ART duration was 350 days (11.6 months). Significant improvements in clinical and immunologic status were noted after 12 months of therapy. ART switches occurred in 701 (54.5%) patients. The cumulative incidence of ART switch at 12 months was 78.4%. Concurrent ART-related toxicities (40.6%) and tuberculosis treatment interactions (28.1%) were the most frequent reasons for ART switch. Baseline AIDS symptoms (hazard rate [HR] = 1.59, 95% confidence interval [CI]: 1.28 to 1.98; P < 0.01) and a CD4 count ≤100 cells/mm3 (HR = 1.20, CI: 1.01 to 1.43; P = 0.04) were independent predictors of ART switch. ART-related clinical toxicity occurred in 341 (26.5%) patients. Peripheral neuropathy was reported most frequently (20.7%). A CD4 count ≤100 cells/mm3 was an independent predictor of clinical toxicity. Conclusions: Excellent clinical and immunologic responses to ART were observed in this urban Kenyan population; however, frequent switches in ART among medication classes because of toxicity or drug interactions may limit the durability of these responses.

1 June 2008 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
CHClaudia A. Hawkins
Claudia A. Hawkins
CQChao Qi
Chao Qi
JWJohn Warren
John Warren
VSValentina Stosor
Valentina Stosor

31 January 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
ALAlexander L Lundberg
Alexander L Lundberg
RLRamón Lorenzo-Redondo
Ramón Lorenzo-Redondo
EOEgon Anderson Ozer
Egon Anderson Ozer
CHClaudia A. Hawkins
Claudia A. Hawkins
JHJudd F. Hultquist
Judd F. Hultquist
LPLori Ann Post
Lori Ann Post
Background: Variants of the SARS-CoV-2 virus carry differential risks to public health. The Omicron (B.1.1.529) variant, first identified in Botswana on November 11, 2021, has spread globally faster than any previous variant of concern. Understanding the transmissibility of Omicron is vital in the development of public health policy. Objective: The aim of this study is to compare SARS-CoV-2 outbreaks driven by Omicron to those driven by prior variants of concern in terms of both the speed and magnitude of an outbreak. Methods: We analyzed trends in outbreaks by variant of concern with validated surveillance metrics in several southern African countries. The region offers an ideal setting for a natural experiment given that most outbreaks thus far have been driven primarily by a single variant at a time. With a daily longitudinal data set of new infections, total vaccinations, and cumulative infections in countries in sub-Saharan Africa, we estimated how the emergence of Omicron has altered the trajectory of SARS-CoV-2 outbreaks. We used the Arellano-Bond method to estimate regression coefficients from a dynamic panel model, in which new infections are a function of infections yesterday and last week. We controlled for vaccinations and prior infections in the population. To test whether Omicron has changed the average trajectory of a SARS-CoV-2 outbreak, we included an interaction between an indicator variable for the emergence of Omicron and lagged infections. Results: The observed Omicron outbreaks in this study reach the outbreak threshold within 5-10 days after first detection, whereas other variants of concern have taken at least 14 days and up to as many as 35 days. The Omicron outbreaks also reach peak rates of new cases that are roughly 1.5-2 times those of prior variants of concern. Dynamic panel regression estimates confirm Omicron has created a statistically significant shift in viral spread. Conclusions: The transmissibility of Omicron is markedly higher than prior variants of concern. At the population level, the Omicron outbreaks occurred more quickly and with larger magnitude, despite substantial increases in vaccinations and prior infections, which should have otherwise reduced susceptibility to new infections. Unless public health policies are substantially altered, Omicron outbreaks in other countries are likely to occur with little warning.